Fragment-based Hit Discovery for the Epigenetic Target BRD3 (poster)
Sygnature Discovery has designed and synthesised a proprietary fragment library with a high degree of
novelty that covers awide range of chemical space. Comprised of over 900 compounds, majority are not
commercially available, the library was designed using the‘rule of 3’as a guideline and with a strong
emphasis on diversity. To demonstrate its effectiveness in fragment-based drug discovery, the library was screened against an
epigenetic target with little previous literature on drug discovery, Bromodomain-containing protein 3 (BRD3,
also known as RING3L).